<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOVIPREP - polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride,  sodium ascorbate and ascorbic acid 
			 </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">MoviPrep® is indicated for cleansing of the colon as a preparation for 
colonoscopy in adults 18 years of age or older.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The MoviPrep dose for colon cleansing for adult patients is 2 
liters (approximately 64 ounces) of MoviPrep solution (with 1 additional liter 
of clear fluids) taken orally prior to the colonoscopy in one of the following 
ways:</p>
<br><ol>
<li>
<span class="Bold"><span class="Emphasis">Split-dose MoviPrep 
regimen:</span></span>  The evening before the colonoscopy, take the first liter 
of MoviPrep solution over one hour (one 8 ounce glass every 15 minutes) and then 
drink 0.5 liters (approximately 16 ounces) of clear fluid.  Then, on the morning 
of the colonoscopy, take the second liter of MoviPrep solution over one hour and 
then drink 0.5 liters of clear liquid at least one hour prior to the start of 
the colonoscopy; or 
</li>
<li>
<span class="Bold"><span class="Emphasis">Evening only (Full-dose) MoviPrep 
regimen:</span></span>  Around 6 PM in the evening before the colonoscopy, take 
the first liter of MoviPrep solution over one hour (one 8 ounce glass every 15 
minutes) and then about 1.5 hours later take the second liter of MoviPrep 
solution over one hour.  In addition, take 1 liter (approximately 32 ounces) of 
additional clear liquid during the evening before the colonoscopy. 
</li>
</ol>
<br><p><span class="Bold"><span class="Emphasis">Preparation of the MoviPrep 
solution:</span></span></p>
<p>MoviPrep solution is prepared by emptying the contents of 1 pouch A and 1 
pouch B into a suitable glass container (or the container provided) and adding 
to the container 1 liter of lukewarm water.  Mix the solution to ensure that the 
ingredients are completely dissolved.  If the patient prefers, the MoviPrep 
solution can be refrigerated prior to drinking. The reconstituted solution 
should be used within 24 hours.</p>
<br><p>After consumption of the first liter of MoviPrep solution, the above mixing 
procedure should be repeated with the second pouch A and pouch B to reconstitute 
the second liter of the MoviPrep solution.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">MoviPrep is available in a carton that contains 4 separate pouches (2 of pouch A 
and 2 of pouch B). Each pouch A contains 100 grams of polyethylene glycol (PEG) 
3350, NF, 7.5 grams of sodium sulfate, USP, 2.691 grams of sodium chloride, USP, 
and 1.015 grams of potassium chloride, USP, plus the following excipients: 
aspartame, NF (sweetener), acesulfame potassium, NF (sweetener), and lemon 
flavoring. Each pouch B contains 4.7 grams of ascorbic acid, USP and 5.9 grams 
of sodium ascorbate, USP.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">MoviPrep is contraindicated in patients who have had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> 
reaction to any of its components.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">MoviPrep should be used with caution in patients with severe 
<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> or perforation, gastric 
retention, toxic <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, or toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span></p>
<br><p><span class="Bold"><span class="Emphasis">General</span></span></p>
<p>Patients with impaired gag reflex and patients prone to <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span> or 
<span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> should be observed during the administration of MoviPrep.  If a 
patient experiences severe <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, 
administration should be slowed or temporarily discontinued until the symptoms 
abate. If <span class="product-label-link" type="condition" conceptid="4129389" conceptname="Gastrointestinal obstruction">gastrointestinal obstruction</span> or perforation is suspected, appropriate 
tests should be performed to rule out these conditions before administration of 
MoviPrep®.  </p>
<br><p>Phenylketonurics: MoviPrep contains phenylalanine – a maximum of 2.33 mg of 
phenylalanine per treatment.</p>
<br><p>No additional ingredients (e.g., flavorings) should be added to the MoviPrep 
solution.</p>
<br><p>Since MoviPrep contains sodium ascorbate and ascorbic acid, MoviPrep should 
be used with caution in patients with glucose-6-phosphate dehydrogenase (G-6-PD) 
deficiency especially G-6-PD deficiency patients with an active <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, with 
a history of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span>, or taking concomitant medications known to precipitate 
hemolytic reactions.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>5.1 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><p>There have been rare reports of generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> 
associated with use of polyethylene glycol colon preparation products in 
patients with no prior history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  The <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> cases were associated 
with electrolyte abnormalities (e.g., <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>).  The 
neurologic abnormalities resolved with correction of fluid and electrolyte 
abnormalities.  Therefore, MoviPrep should be used with caution in patients 
using concomitant medications that increase the risk of electrolyte 
abnormalities [such as diuretics or angiotensin converting enzyme 
(ACE)-inhibitors] or in patients with known or suspected <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.  Consider 
performing baseline and post-colonoscopy laboratory tests (sodium, potassium, 
calcium, creatinine, and BUN) in these patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<a href="http://"></a>6.1 Clinical Studies Experience<p class="First">In the MoviPrep trials, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span>, anal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, 
<span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> were some of the most common adverse 
reactions to MoviPrep administration.  Since <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was considered as a part 
of the efficacy of MoviPrep, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was not defined as an adverse reaction in 
the clinical studies.  Tables 1 and 2 display the most common drug-related 
adverse reactions of MoviPrep and its comparator in the controlled MoviPrep 
trials.</p>
<a name="i558ed33d-555f-4fa7-8601-88d8007f204a"></a><table width="80%">
<caption><span>Table 1: The Most Common Drug-Related Adverse Reactions*   (≥ 2%) in the Study of MoviPrep vs. 4 liter Polyethylene Glycol plus Electrolytes Solution</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">MoviPrep®</span></span></p>
<p><span class="Bold"><span class="Emphasis">(split dose)</span></span></p>
<span class="Bold"><span class="Emphasis">N=180</span></span>
</td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">4L PEG + E</span></span></span></span>†<span class="Bold"><span class="Emphasis"> <span class="Bold"><span class="Emphasis"> </span></span></span></span></p>
<span class="Bold"><span class="Emphasis">N=179 </span></span>    <br>
</td>
</tr>
<tr>
<td><br></td>
<td>n (% = n/N)<br>
</td>
<td>n (% = n/N)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span><br>
</td>
<td>35 (19.4)<br>
</td>
<td>32 (17.9)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td>26 (14.4)<br>
</td>
<td>36 (20.1)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>
</td>
<td>24 (13.3)<br>
</td>
<td>27 (15.1)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td>14 (7.8)<br>
</td>
<td>23 (12.8)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper abdominal pain</span><br>
</td>
<td>10 (5.6)<br>
</td>
<td>11 (6.1)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br>
</td>
<td>5 (2.8)<br>
</td>
<td>2 (1.1)<br>
</td>
</tr>
</tbody>
</table>*     Drug-related adverse reactions were adverse events that were possibly, probably, 
or definitely related to the study drug.<br>†     4L PEG + E is 4 liter Polyethylene Glycol plus Electrolytes Solution <br><br><a name="ice579cc7-df5d-4383-8648-1918cfbfd8d9"></a><table width="100%">
<caption><span>Table 2: The Most Common Drug-Related Adverse Reactions*    (≥ 5%) in the Study of MoviPrep vs. 90 mL Oral Sodium Phosphate Solution</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<span class="Bold"><span class="Emphasis">MoviPrep®</span></span><br><span class="Bold"><span class="Emphasis">(evening-only)</span></span><br><span class="Bold"><span class="Emphasis">(full dose)</span></span><br><span class="Bold"><span class="Emphasis">N=169</span></span>
</td>
<td>
<span class="Bold"><span class="Emphasis">90 mL OSPS</span></span>†<span class="Bold"><span class="Emphasis"></span></span><br><span class="Bold"><span class="Emphasis">N=171</span></span>
</td>
</tr>
<tr>
<td><br></td>
<td>n (% = n/N)<br>
</td>
<td>n (% = n/N)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span><br>
</td>
<td>101 (59.8)<br>
</td>
<td>70 (40.9)<br>
</td>
</tr>
<tr>
<td>Anal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span><br>
</td>
<td>87 (51.5)<br>
</td>
<td>89 (52.0)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span><br>
</td>
<td>80 (47.3)<br>
</td>
<td>112 (65.5)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td>80 (47.3)<br>
</td>
<td>80 (46.8)<br>
</td>
</tr>
<tr>
<td>Abdominal paint<br>
</td>
<td>66 (39.1)<br>
</td>
<td>55 (32.2)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span><br>
</td>
<td>59 (34.9)<br>
</td>
<td>49 (28.7)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span><br>
</td>
<td>57 (33.7)<br>
</td>
<td>51 (29.8)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">Hunger</span><br>
</td>
<td>51 (30.2)<br>
</td>
<td>121 (70.8)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span><br>
</td>
<td>45 (26.6)<br>
</td>
<td>90 (52.6)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>
</td>
<td>12 (7.1)<br>
</td>
<td>14 (8.2)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td>11 (6.5)<br>
</td>
<td>31 (18.1)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td>3 (1.8)<br>
</td>
<td>9 (5.3)<br>
</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span><br>
</td>
<td>0 (0)<br>
</td>
<td>10 (5.8)<br>
</td>
</tr>
<tr class="Last">
<td><span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">Hyperphosphatemia</span><br>
</td>
<td>0 (0)<br>
</td>
<td>10 (5.8)<br>
</td>
</tr>
</tbody>
</table>
<span class="Bold"><span class="Emphasis"></span></span><br>*     Drug-related adverse reactions were adverse events that were possibly, probably, 
or definitely related to the study drug. In addition to the recording of 
spontaneous adverse events, patients were also specifically asked about the 
occurrence of the following symptoms: <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, anal irritations, abdominal 
<span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> or fullness, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleep loss</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> sensation, 
<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> sensation, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.<br>†     OSPS is Oral Sodium Phosphate Solution<br><br><p>Isolated cases of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, and anaphylactic 
reaction have been reported with PEG-based products and may represent allergic 
reactions.</p>
<p>Published literature contains isolated reports of serious adverse events 
following the administration of PEG-based products in patients over 60 years of 
age. These adverse events included upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> from a 
Mallory-Weiss tear, <span class="product-label-link" type="condition" conceptid="22955" conceptname="Perforation of esophagus">esophageal perforation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>, and <span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">acute pulmonary edema</span> 
after aspirating the PEG-based preparation.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>6.2 Postmarketing Experience<p>In addition to adverse events reported from clinical trials, the 
following adverse events have been identified during post-approval use of 
MoviPrep. Because they are reported voluntarily from a population of unknown 
size, estimates of frequency cannot be made. These events have been chosen for 
inclusion due to either their seriousness, frequency of reporting or causal 
connection to MoviPrep, or a combination of these factors. </p>
<p><span class="Bold"><span class="Emphasis">General:</span></span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> 
reactions including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, lip and <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, 
<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> and <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>.</p>
<br>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">Oral medication administered within 1 hour of the start of administration of 
MoviPrep may be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> from the gastrointestinal tract and the medication may 
not be absorbed.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<a href="http://"></a>8.1 Pregnancy: Teratogenic Effects<p class="First">Pregnancy Category C. Animal reproduction studies have not been 
performed with MoviPrep.  It is also not known if MoviPrep can cause fetal harm 
when administered to a pregnant woman or can affect reproductive capacity. 
MoviPrep should be given to a pregnant woman only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8.3 Nursing Mothers<p>Because many drugs are excreted in human milk, caution should be 
exercised when MoviPrep is administered to a nursing woman.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8.4 Pediatric Use<p>The safety and effectiveness of MoviPrep in pediatric patients 
has not been established.<br></p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>8.5 Geriatric Use<p>Of the 413 patients in clinical studies receiving MoviPrep, 91 
(22%) patients were aged 65 or older, while 25 (6%) patients were over 75 years 
of age.  No overall differences in safety or effectiveness were observed between 
geriatric patients and younger patients, and other reported clinical experience 
has not identified differences in responses between geriatric patients and 
younger patients, but greater sensitivity of some older individuals cannot be 
ruled out.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">There have been no reported cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with MoviPrep.  Purposeful or 
gross accidental ingestion of more than the recommended dose of MoviPrep might 
be expected to lead to severe <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>, including <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> 
and/or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, as well as <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, with signs and 
symptoms of these disturbances. The patient who has taken an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be 
monitored carefully, and treated symptomatically for complications until stable.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">MoviPrep® consists of 4 separate pouches (2 of pouch A and 2 of pouch B) 
containing white to yellow powder for reconstitution.  Each pouch A contains 100 
grams of polyethylene glycol (PEG) 3350, NF, 7.5 grams of sodium sulfate, USP, 
2.691 grams of sodium chloride, USP, and 1.015 grams of potassium chloride, USP, 
plus the following excipients: aspartame, NF (sweetener), acesulfame potassium, 
NF (sweetener), and lemon flavoring. Each pouch B contains 4.7 grams of ascorbic 
acid, USP and 5.9 grams of sodium ascorbate, USP.  When 1 pouch A and 1 pouch B 
are dissolved together in water to a volume of 1 liter, MoviPrep (PEG-3350, 
sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and 
ascorbic acid) is an oral solution having a lemon taste.<br> <br>The entire, 
reconstituted, 2-liter MoviPrep colon preparation contains 200 grams of 
PEG-3350, 15 grams of sodium sulfate, 5.38 grams of sodium chloride, 2.03 grams 
of potassium chloride, 9.4 grams of ascorbic acid, and 11.8 grams of sodium 
ascorbate plus the following excipients: aspartame (sweetener), acesulfame 
potassium (sweetener), and lemon flavoring.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<p class="First">MoviPrep produces a watery stool leading to cleansing of the 
colon. The osmotic activity of polyethylene glycol 3350, sodium sulfate, sodium 
chloride, potassium chloride, sodium ascorbate, and ascorbic acid, when taken 
with 1 liter of additional clear fluid, usually results in no net absorption or 
excretion of ions or water. </p>
<br><p>The pharmacokinetics of MoviPrep have not been studied in patients with renal 
or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<a href="http://"></a>13.1 Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p class="First">Long-term studies in animals to evaluate the carcinogenic 
potential have not been performed with MoviPrep®.  Studies to evaluate potential 
for impairment of fertility or mutagenic potential have not been performed with 
MoviPrep®.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<p class="First">The colon cleansing efficacy and safety of MoviPrep was evaluated 
in two randomized, actively-controlled, multi-center, investigator-blinded, 
phase 3 trials in patients scheduled to have an elective colonoscopy. </p>
<br><p>In the first study, patients were randomized to one of the following two 
colon preparation treatments:  1) 2 liters of MoviPrep with 1 additional liter 
of clear fluid split into two doses (during the evening before and the morning 
of the colonoscopy) and 2) 4 liters of polyethylene glycol plus electrolytes 
solution (4L PEG + E) split into two doses (during the evening before and the 
morning of the colonoscopy).  Patients were allowed to have a morning breakfast, 
a light lunch, clear soup and/or plain yogurt for dinner.  Dinner had to be 
completed at least one hour prior to initiation of the colon preparation 
administration.  </p>
<br><p>The primary efficacy endpoint was the proportion of patients with effective 
colon cleansing as judged by blinded gastroenterologists on the basis of 
videotapes recorded during the colonoscopy. <br>The blinded gastroenterologists 
graded the colon cleansing twice (during introduction and withdrawal of the 
colonoscope) and the poorer of the two assessments was used in the primary 
efficacy analysis.  </p>
<br><p>The efficacy analysis included 308 adult patients who had an elective 
colonoscopy.  Patients ranged in age from 18 to 88 years old (mean age about 59 
years old) with 52% female and 48% male patients.  Table 3 displays the results.</p>
<a name="i5b00a400-f423-4441-8be1-520ff67a1f5e"></a><table width="100%">
<caption><span>Table 3: Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 4 Liter Polyethylene Glycol plus Electrolytes Solution</span></caption>
<tbody class="Headless">
<tr class="First">
<td><br></td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">Responders</span></span></p>
<span class="Bold"><span class="Emphasis">A</span></span>*<span class="Bold"><span class="Emphasis">   or B</span></span>†<span class="Bold"><span class="Emphasis"> </span></span><span class="Bold"><span class="Emphasis">  (%)</span></span><br>
</td>
<td>
<span class="Bold"><span class="Emphasis">C</span></span>‡<span class="Bold"><span class="Emphasis">   (%)</span></span><br>
</td>
<td>
<span class="Bold"><span class="Emphasis">D</span></span>§<span class="Bold"><span class="Emphasis">   (%)</span></span>
</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">MoviPrep®</span></span></p>
<span class="Bold"><span class="Emphasis">    (N=153)</span></span><br>
</td>
<td>88.9<br>
</td>
<td>9.8<br>
</td>
<td>1.3<br>
</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">4L PEG + E</span></span></span></span>¶<span class="Bold"><span class="Emphasis"> <span class="Bold"><span class="Emphasis"> </span></span></span></span></p>
<span class="Bold"><span class="Emphasis">    (N=155)</span></span><br>
</td>
<td>94.8<br>
</td>
<td>4.5<br>
</td>
<td>0.6<br>
</td>
</tr>
</tbody>
</table>
<br>*     A: colon empty and clean or presence of clear liquid, but easily removed by 
suction <br>†     B: brown liquid or semisolid remaining amounts of stool, fully removable by 
suction or displaceable, thus allowing a complete visualization of the gut 
mucosa <br>‡     C: semisolid amounts of stool, only partially removable with a risk of 
incomplete visualization of the gut mucosa <br><span class="Bold"><span class="Emphasis"></span></span>§     D: semisolid or solid amounts of stool; consequently colonoscopy incomplete or 
needed to be terminated. 4 L PEG+E's responder rate was not significantly higher 
than MoviPrep's responder rate.<br>¶     4L PEG + E is 4 Liter Polyethylene Glycol plus Electrolytes Solution<br><br><p>In the second study, patients were randomized to one of the following two 
colon preparation treatments:  1) 2 liters of MoviPrep with 1 additional liter 
of clear fluid in the evening prior to the colonoscopy and 2) 90 mL of oral 
sodium phosphate solution (90 mL OSPS) with at least 2 liters of additional 
clear fluid during the day and evening prior to the colonoscopy.  Patients 
randomized to MoviPrep therapy were allowed to have a morning breakfast; a light 
lunch; and clear soup and/or plain yogurt for dinner.  Dinner had to be 
completed at least one hour prior to initiation of the colon preparation 
administration.<br> <br>The primary efficacy endpoint was the proportion of 
patients with effective colon cleansing as judged by the colonoscopist and one 
blinded gastroenterologist (on the basis of videotapes recorded during the 
colonoscopy).  In case of a discrepancy between the colonoscopist and the 
blinded gastroenterologist, a second blinded gastroenterologist made the final 
efficacy determination.</p>The efficacy analysis included 280 adult patients who had an elective 
colonoscopy.  Patients ranged in age from 21 to 76 years old (mean age about 53 
years old) with 47% female and 53% male patients.  Table 4 displays the results.<br><a name="ie127cd5c-de17-4aee-885a-a5c288b2575d"></a><table width="100%">
<caption><span>Table 4: Effectiveness of Overall Colon Cleansing in the Study of MoviPrep vs 90mL Oral Sodium Phosphate Solution </span></caption>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold"><span class="Emphasis"></span></span><br>
</td>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">Responders</span></span></p>
<span class="Bold"><span class="Emphasis">A</span></span>*<span class="Bold"><span class="Emphasis"> or B</span></span>†<span class="Bold"><span class="Emphasis"> (%)</span></span><br>
</td>
<td>
<span class="Bold"><span class="Emphasis">C</span></span>‡<span class="Bold"><span class="Emphasis"> (%)</span></span>
</td>
<td>D§ (%)</td>
</tr>
<tr>
<td>
<p class="First"><span class="Bold"><span class="Emphasis">MoviPrep®</span></span></p>
<span class="Bold"><span class="Emphasis">(N=137)</span></span>
</td>
<td>73.0<br>
</td>
<td>23.4<br>
</td>
<td>3.6</td>
</tr>
<tr class="Last">
<td>
<p class="First"><span class="Bold"><span class="Emphasis">90 mL OSPS</span></span>¶ </p>
<span class="Bold"><span class="Emphasis">(N=143)</span></span><br>
</td>
<td>64.4<br>
</td>
<td>29.4<br>
</td>
<td>6.3<br>
</td>
</tr>
</tbody>
</table>
<br><br>*     A: empty and clean or clear liquid (transparent, yellow, or green) <br>†     B: brown liquid or semisolid remaining small amounts of stool, fully removable 
by suction or displaceable allowing a complete visualization of the underlying 
mucosa <br>‡     C: semi solid only partially removable/displaceable stools; risk of incomplete 
examination of the underlying mucosa <br>§     D: heavy and hard stool making the segment examination uninterpretable and, 
consequently, the colonoscopy needed to be terminated <br>¶     <br>OSPS is Oral Sodium Phosphate Solution <br>MoviPrep's responder rate was not significantly higher than OSPS's responder 
rate.<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">MoviPrep® is supplied in powdered form.  MoviPrep is administered 
as an oral solution after reconstitution. </p>
<p>NDC 54868-5890-0, MoviPrep, single use carton. <br><br></p>
<p>Each carton contains a disposable container for reconstitution of MoviPrep® 
and an inner carton containing 4 pouches (2 of pouch A and 2 of pouch 
B).</p>
<br><br><p><span class="Bold"><span class="Emphasis">Rx only</span></span></p>
<p><span class="Bold"><span class="Emphasis">STORAGE</span></span><br><br>Store 
carton/container at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). When 
reconstituted, store upright and keep solution refrigerated. Use within 24 
hours.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Important Precautions Regarding MOVIPREP</p>
<p>MoviPrep produces a watery stool which cleanses the colon before 
colonoscopy.  It is recommended that patients receiving MoviPrep be advised to 
adequately hydrate before, during, and after the use of MoviPrep. Patients may 
have clear soup and/or plain yogurt for dinner, finishing the evening meal at 
least one hour prior to the start of MoviPrep treatment.  No solid food should 
be taken from the start of MoviPrep treatment until after the 
colonoscopy.</p>
<br><p>What Patients Should Know About Adverse Reactions</p>
<p>The first bowel movement may occur approximately 1 hour after the start of 
MoviPrep administration. <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">Abdominal bloating</span> and <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> may occur before the 
first bowel movement. If severe <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> or <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span> occurs, stop 
drinking temporarily or drink each portion at longer intervals until these 
symptoms disappear.</p>
<br><br><p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">Manufactured by:</span></span><br></span></span>Norgine 
B.V.<br>Hogehilweg 7<br>1101 CA Amsterdam Zuidoost<br>Netherlands </p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">For:</span></span><br></span></span>Salix Pharmaceuticals, 
Inc.<br>Morrisville, NC 27560</p>
<p>© 2006 Salix Pharmaceuticals, Inc.<br>VENART xxx-x/June 09</p>
<p>Product protected by U.S. Patent No. 7169381 and other pending applications</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis"><span class="Bold"><span class="Emphasis">MoviPrep®</span></span><br></span></span>(PEG-3350, Sodium 
Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid 
for Oral Solution) </p>
<p>Phenylketonurics:<br>contains phenylalanine – a maximum of 2.33 mg per course 
of treatment.</p>
<p>This carton contains<br>One container for reconstitution of <span class="Bold"><span class="Emphasis">MoviPrep®</span></span></p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6ca2803e-a4d6-4e57-a910-13237c93a4ce&amp;name=package%20label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOVIPREP 		
					</strong><br><span class="contentTableReg">polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride,  sodium ascorbate and ascorbic acid kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5890(NDC:65649-201)</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5890-0</td>
<td class="formItem">1  in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">2 POUCH </td>
<td class="formItem">2 L</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">2 POUCH </td>
<td class="formItem">2 L</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>POUCH A 		
					</strong><br><span class="contentTableReg">polyethylene glycol 3350,sodium sulfate,anhydrous,sodium chloride,potassium chloride solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5890</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POLYETHYLENE GLYCOL 3350</strong> (POLYETHYLENE GLYCOL 3350) </td>
<td class="formItem">POLYETHYLENE GLYCOL 3350</td>
<td class="formItem">100 g  in 1 L</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM SULFATE</strong> (SODIUM CATION) </td>
<td class="formItem">SODIUM SULFATE</td>
<td class="formItem">7.5 g  in 1 L</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM CHLORIDE</strong> (SODIUM CATION) </td>
<td class="formItem">SODIUM CHLORIDE</td>
<td class="formItem">2.69 g  in 1 L</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">1.015 g  in 1 L</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LEMON</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 L in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021881</td>
<td class="formItem">05/30/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>POUCH B 		
					</strong><br><span class="contentTableReg">ascorbic acid, sodium ascorbate solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5890</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ASCORBIC ACID</strong> (ASCORBIC ACID) </td>
<td class="formItem">ASCORBIC ACID</td>
<td class="formItem">4.7 g  in 1 L</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM ASCORBATE</strong> (SODIUM CATION) </td>
<td class="formItem">SODIUM ASCORBATE</td>
<td class="formItem">5.9 g  in 1 L</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACESULFAME POTASSIUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 L in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021881</td>
<td class="formItem">05/30/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021881</td>
<td class="formItem">05/30/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ff3c9070-c458-4917-97a8-39c11edddd36</div>
<div>Set id: 6ca2803e-a4d6-4e57-a910-13237c93a4ce</div>
<div>Version: 1</div>
<div>Effective Time: 20091130</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
